Trial Profile

Using TOfogliflozin for Possible better Intervention against Atherosclerosis for Type 2 Diabetes Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofogliflozin (Primary) ; Antihyperglycaemics
Indications Atherosclerosis; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms UTOPIA

Most Recent Events

16 Jun 2020 Primary endpoint (Changes in the IMT value (mean and max IMT) during a 104-week treatment period measured by carotid arterial echography Particularly focusing on the change of the mean of right and left meanIMT during 104 weeks of the study period) has not been met, as per results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
05 Jul 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com